PTO/SB/08b (07-09) Approved for use through 07/31/2012. OMB 0651-0031

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless il contains a valid OMB control number

Substitute for form 1449/PTO			Complete if Known		
			Application Number	10/560,519-Conf. #5664	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Filing Date	March 20, 2006	
			First Named Inventor	Inge Dorthe Hansen	
			Art Unit	1623	
			Examiner Name	M. C. Henry	
heet 1	of	1	Attorney Docket Number	HOI-14302/16	

	,		U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-20020035119	03-21-2002	Kumar et al.	
	 				

		FOREI	GN PATENT	DOCUMENTS	***************************************	
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁴
	BA	WO-00/35460	06-22-2000	Gilead Sciences, Inc.		V
	BB	WO-99/63970	12-16-1999	Pharmacia & Upjohn Co.		V

Examiner initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), dale, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	CA	Ohara, Y. et al., Tablet for treating hyperlipidemia, comprises compression-molded formulation comprising mixture of pravastatin sodium and additive which comprises synthetic calcium silicate as a stabilizer, WPI Abstract No. 2001-613851 for JP2001233765, Aug. 28, 2001	
	СВ	Yoshimura, T., Preparation of high calcium content medicine, medical drinks, etc. containing active substance powder or extract of chrysanthemum, WPI Abstract No. 1988-215499 for JP63150227, June 22, 1988	

Examiner Signature	/Michael Henry/	Date Considered	04/14/2011
Signature		Considered	04/14/2011

"EXAMINER, Initial if inference considered, whether or not cluston is in conformance with MEPE 800. Draw like through clusten if not in conformance and not considered, included copy of this form with next communication to applicate. If CPT Not. These applications (s) which are manded with an single size in CPT or to be CPT in Not. These applications (s) which are manded with an single size in CPT or to be CPT in Not. These applications with respect to the CPT or to be CPT in Not. The separation of the control of the CPT or to be CPT